In the two years since the Tear Film & Ocular Surface Society second Dry Eye Workshop (TFOS DEWS II) reports were published, most would agree that dry eye disease (DED) is closer to reaching household name status, becoming a disease that’s more widely recognised and acknowledged by clinicians and more readily reported by patients. Where once DED or meibomian gland dysfunction (MGD) might have been overlooked or simply disregarded, there is a greater acknowledgement of the critical role the ocular surface condition can play in quality of life, optimising visual quality and surgical outcomes, and much credit should go to TFOS for this paradigm shift.
Premium subscriber content
Sign in if you have a Digital or Print + Digital subscription. Don’t have one yet? Digital subscribers get full access to this article from $40/year +GST.
- Premium exclusive content
- Full digital magazine archive
- Early access to new articles
